中国医学前沿杂志（电子版）
中國醫學前沿雜誌（電子版）
중국의학전연잡지（전자판）
CHINESE JOURNAL OF THE FRONTIERS OF MEDICAL SCIENCE(ELECTRONIC VERSION)
2014年
10期
43-45
,共3页
白细胞介素-33%炎性肠病%溃疡性结肠炎%克罗恩病
白細胞介素-33%炎性腸病%潰瘍性結腸炎%剋囉恩病
백세포개소-33%염성장병%궤양성결장염%극라은병
Interleukin -33,Inlfammatory bowel disease%Ulcerative colitis%Crohn's disease
目的：研究白细胞介素（IL）-33及其受体ST2介导的细胞因子在小儿炎性肠病中的变化，探索IL-33及其受体ST2在小儿炎性肠病中的免疫调节作用。方法将44例患儿分为溃疡性结肠炎（UC）组和克罗恩病（CD）组，比较两组患儿治疗前后外周血中IL-33、IL-4、IL-6、IL-5、IL-13、γ-干扰素（INF-γ）、肿瘤坏死因子-α（TNF-α）的变化。结果治疗前两组患儿IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α比较差异无显著性（P＞0.05）；治疗后两组患儿IL-33、IL-5、IL-13较治疗前显著降低（P＜0.05）， IL-6、INF-γ、TNF-α较治疗前显著升高（P＜0.05）；治疗后两组患儿IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α比较差异无显著性（P＞0.05）。结论炎性肠病患儿肠道组织中浸润的巨噬细胞是IL-33的主要来源，IL-33的增加会使Th2型细胞因子（IL-5、IL-13）明显增加，而Th1型细胞因子（INF-γ、IL-6、TNF-α）明显减少。IL-33可有效缓解炎性肠病的进展。
目的：研究白細胞介素（IL）-33及其受體ST2介導的細胞因子在小兒炎性腸病中的變化，探索IL-33及其受體ST2在小兒炎性腸病中的免疫調節作用。方法將44例患兒分為潰瘍性結腸炎（UC）組和剋囉恩病（CD）組，比較兩組患兒治療前後外週血中IL-33、IL-4、IL-6、IL-5、IL-13、γ-榦擾素（INF-γ）、腫瘤壞死因子-α（TNF-α）的變化。結果治療前兩組患兒IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α比較差異無顯著性（P＞0.05）；治療後兩組患兒IL-33、IL-5、IL-13較治療前顯著降低（P＜0.05）， IL-6、INF-γ、TNF-α較治療前顯著升高（P＜0.05）；治療後兩組患兒IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α比較差異無顯著性（P＞0.05）。結論炎性腸病患兒腸道組織中浸潤的巨噬細胞是IL-33的主要來源，IL-33的增加會使Th2型細胞因子（IL-5、IL-13）明顯增加，而Th1型細胞因子（INF-γ、IL-6、TNF-α）明顯減少。IL-33可有效緩解炎性腸病的進展。
목적：연구백세포개소（IL）-33급기수체ST2개도적세포인자재소인염성장병중적변화，탐색IL-33급기수체ST2재소인염성장병중적면역조절작용。방법장44례환인분위궤양성결장염（UC）조화극라은병（CD）조，비교량조환인치료전후외주혈중IL-33、IL-4、IL-6、IL-5、IL-13、γ-간우소（INF-γ）、종류배사인자-α（TNF-α）적변화。결과치료전량조환인IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α비교차이무현저성（P＞0.05）；치료후량조환인IL-33、IL-5、IL-13교치료전현저강저（P＜0.05）， IL-6、INF-γ、TNF-α교치료전현저승고（P＜0.05）；치료후량조환인IL-33、IL-4、IL-6、IL-5、IL-13、INF-γ、TNF-α비교차이무현저성（P＞0.05）。결론염성장병환인장도조직중침윤적거서세포시IL-33적주요래원，IL-33적증가회사Th2형세포인자（IL-5、IL-13）명현증가，이Th1형세포인자（INF-γ、IL-6、TNF-α）명현감소。IL-33가유효완해염성장병적진전。
ObjectiveTo study on changes in interleukin (IL)-33 and cell factors of its receptor mediated by ST2 in children within lfammatory bowel disease and to explore immune regulatory effects of IL-33 and its receptor ST2 on children with inlfammatory bowel disease.Method44 patients were divided into ulcerative colitis (UC) group and Crohn's disease (CD) group, the changes in IL-33 peripheral blood and IL-4, IL-6, IL-5, IL-13 and gamma-interferon (INF-γ) and tumor necrosis factor alpha (TNF-α) of patients in two groups before and after treatment were compared.ResultThe comparisons in IL-33, IL-4, IL-6, IL-5, IL-13, INF-γ and TNF-α were no signiifcantly different before treatment (P>0.05), the levels of IL-33, IL-5 and IL-13 of patients in two groups were signiifcantly lower when compared to those after treatment (P<0.05), and the levels of IL-6, INF-γ and TNF-α of patients in two groups were signiifcantly increased when compared to those after treatment (P<0.05), and the comparisons in IL-33, IL-4, IL-6, IL-5, IL-13, INF-γ and TNF-α were not signiifcantly different (P>0.05). ConclusionMacrophages inifltrating in intestinal tissues of patients with inlfammatory bowel disease are main sources of IL-33, the rise in the quantity of IL-33 will signiifcantly increase the quantity of Th2-type cytokines (IL-5, IL-13), while the number of Th1-type cell factors (INF-γ, IL-6, TNF-α) will signiifcantly reduced. IL-33 is capable of effectively alleviating the progress of inlfammatory bowel disease.
